REGENXBIO(RGNX) - 2024 Q2 - Quarterly Results

EXHIBIT 99.1 REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights • Company remains on track for its first BLA filing in 2024 and is accelerating progress toward pivotal trial initiation for Duchenne (H2 2024) and diabetic retinopathy (H1 2025) o New, positive data from Phase II AFFINITY DUCHENNE ®trial of RGX-202 demonstrates consistent high expression of microdystrophin across treated patients in all age groups o Successful End-of-Phase II meeting with FDA for RGX-202 ...